Targeting non-canonical nuclear factor-κB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting non-canonical nuclear factor-κB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis
Authors
Keywords
-
Journal
RHEUMATOLOGY
Volume 56, Issue 2, Pages 294-302
Publisher
Oxford University Press (OUP)
Online
2016-10-06
DOI
10.1093/rheumatology/kew393
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nuclear Factor- B-inducing Kinase Is Expressed in Synovial Endothelial Cells in Patients with Early Arthritis and Correlates with Markers of Inflammation: A Prospective Cohort Study
- (2015) K. I. Maijer et al. JOURNAL OF RHEUMATOLOGY
- Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling
- (2015) Evan M Cherry et al. Molecular Cancer
- Targeting of proangiogenic signalling pathways in chronic inflammation
- (2015) Sander W. Tas et al. Nature Reviews Rheumatology
- Inhibitors of angiogenesis: Ready for prime time?
- (2014) Chrissta X. Maracle et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Lymphotoxin- 1 2 and LIGHT Induce Classical and Noncanonical NF- B-Dependent Proinflammatory Gene Expression in Vascular Endothelial Cells
- (2014) L. A. Madge et al. JOURNAL OF IMMUNOLOGY
- NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis
- (2014) Ae R Noort et al. JOURNAL OF PATHOLOGY
- Lymphotoxin-LIGHT Pathway Regulates the Interferon Signature in Rheumatoid Arthritis
- (2014) Jadwiga Bienkowska et al. PLoS One
- Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure–activity relationship, and co-crystal structures
- (2013) Kexue Li et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- NIK Controls Classical and Alternative NF- B Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells
- (2013) L. Odqvist et al. CLINICAL CANCER RESEARCH
- An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
- (2013) Alicia S Chung et al. NATURE MEDICINE
- Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis
- (2012) Palanisamy Kanakaraj et al. mAbs
- A Heterogeneous In Vitro Three Dimensional Model of Tumour-Stroma Interactions Regulating Sprouting Angiogenesis
- (2012) Pedro Correa de Sampaio et al. PLoS One
- Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis
- (2012) K. Kayakabe et al. RHEUMATOLOGY
- Double Anti-angiogenic and Anti-inflammatory Protein Valpha Targeting VEGF-A and TNF-α in Retinopathy and Psoriasis
- (2011) Keehoon Jung et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Pathogenesis of Rheumatoid Arthritis
- (2011) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non-canonical NF-κB signaling pathway
- (2010) Shao-Cong Sun CELL RESEARCH
- Lymphotoxin-αβ heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis
- (2010) Judy Young et al. CYTOKINE
- Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts
- (2010) Flavia Calmon-Hamaty et al. CYTOKINE
- Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis
- (2009) Beatrix Bartok et al. IMMUNOLOGICAL REVIEWS
- IL-6/sIL-6R trans-signalling, but not TNF-α induced angiogenesis in a HUVEC and synovial cell co-culture system
- (2009) Misato Hashizume et al. RHEUMATOLOGY INTERNATIONAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started